Juggling Gene Therapies: Sarepta's Focus Grows, With Many Balls In The Air
Executive Summary
CEO Doug Ingram talked with Scrip about Sarepta's plans to quickly build out a gene therapy pipeline, potentially launch another exon-skipping drug this year and to develop micro-dystrophin for Duchenne muscular dystrophy.
You may also be interested in...
Sarepta Surprised By CRL For Exon 53-Skipping DMD Drug Golodirsen
The US FDA issued a complete response letter rejecting golodirsen based on risk of infection at intravenous infusion ports and preclinical renal toxicity.
Capricor’s Interim Data Could Offer Hope For Older DMD Patients
Although only interim data from six treated patients, Capricor’s Phase II DMD study shows improvements in upper limb performance, grip strength and respiration. Cardiac performance shows positive trend, but not yet statistical significance.
Heralding Change: Product Pipeline Advances To Watch Out For In Q3
Key events that could move innovative product candidates nearer the market in the third quarter of 2019 are highlighted in a new Biomedtracker/Meddevicetracker report.